A novel therapeutic vaccine targeting the soluble TNFα receptor II to limit the progression of cardiovascular disease: AtheroVax™

Overview of attention for article published in Frontiers in Cardiovascular Medicine, July 2023

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age and source (74th percentile)

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 3 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 2 X users, with an upper bound of 54,841 followers.

@drkaracenk Hocanın haberi yok ama sırada ne var? https://t.co/2RjTmYh14I

20 Jul 2023

Reply Repost Favourite

A novel therapeutic vaccine targeting the soluble TNFα receptor II to limit the progression of cardiovascular disease: AtheroVax™ https://t.co/YzTgvY9l0q

19 Jul 2023

Reply Repost Favourite

New Research: A novel therapeutic vaccine targeting the soluble TNFα receptor II to limit the progression of cardiovascular disease: AtheroVax™: The burden of atherosclerotic cardiovascular disease contributes to a large proportion of… #cardiovascular http

18 Jul 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.